Veterinary prescription required (Whats this?)

Benazecare is indicated for the treatment of congestive heart failure in dogs and the treatment of chronic renal insufficiency in cats.

After oral administration, Benazepril is rapidly absorbed from the gastrointestinal tract and hydrolysed into Benazeprilat, a highly specific and potent inhibitor of angiotensin converting enzyme (ACE). Benazeprilat produces significant inhibition of plasma ACE activity for more than 24 hours after a single dose in both dogs and cats. Inhibition of ACE leads to a reduced conversion of inactive angiotensin I into angiotensin II and therefore reduction in the effects mediated by angiotensin II, including vasoconstriction of both arteries and veins, retention of sodium and water by the kidney and remodelling effects (including pathological cardiac hypertrophy and degenerative renal changes).

In dogs with heart failure, Benazeprilat lowers the blood pressure and volume loading effect on the heart. In cats with renal insufficiency, Benazeprilat reduces the protein loss in urine and normalises the elevated glomerular capillary pressure and reduces systemic blood pressure. Reduction in glomerular hypertension retards the progression of kidney disease by inhibition of further damage to the kidneys. Benazepril has been shown to increase the appetite, quality of life and the survival time of cats particularly in advanced disease.

Benazeprilat is excreted equally by both biliary and urinary routes in dogs and primarily via the biliary route in cats and therefore no adjustment of the dose of Benazecare is necessary in the treatment of cases with renal insufficiency. Onset of clinical efficacy can be expected approximately 1 week after initiation of treatment with benazepril hydrochloride